Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 3/2022

01-03-2022 | Alzheimer's Disease | Original Article

Investigation of the peripheral inflammation (neutrophil–lymphocyte ratio) in two neurodegenerative diseases of the central nervous system

Authors: Sonat Pınar Kara, Bengü Altunan, Aysun Unal

Published in: Neurological Sciences | Issue 3/2022

Login to get access

Abstract

Introduction

Alzheimer’s disease (AD), and idiopathic Parkinson’s disease (IPD) are the neurodegenerative diseases of the central nervous system (CNS). Cognitive impairment is on the forefront in AD. However, IPD is a movement disorder. Inflammation was suggested to have an effect in the pathophysiology of these two diseases. Neutrophil–lymphocyte ratio (NLR) was shown to be a possible marker showing the peripheral inflammation. We aimed to investigate the NLR of patiens with the diagnosis of AD, and IPD, and individuals with no neurodegenerative disease.

Materials and methods

A total of 100 patients with the diagnosis of IPD, and 94 with diagnosis of AD, and 61 healthy controls were included into the study. All the demographic, clinical, and laboratory data were retrospectively obtained from the hospital automated database system.

Results

The NLR in the IPD group was found statistically significantly higher compared with the control group and the AD group (p < 0.001, p = 0.04, respectively). The age-adjusted values were statistically analyzed because of age difference. No statistically significant difference was detected between AD and control groups in terms of NLR (p = 0.6). The age-adjusted NLR value in the Parkinson’s group was found significantly higher compared to the control group (p = 0.02) and Alzheimer’s group (p = 0.03).

Discussion

Chronic inflammation has an important role in the emergence and progression of the chronic neurodegenerative diseases of the CNS. Our results show that the inflammation in the peripheral blood in IPD was more significant compared with the inflammation in AD.
Literature
1.
2.
Avila J, Lucas JJ, Perez M et al (2004) Role of tau protein in both physiological and pathological conditions. Physiol Rev 84:361–384PubMedCrossRef
3.
Alonso AC, Grundke-Iqbal I, Iqbal K (1996) Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2:783–787PubMedCrossRef
4.
Kinney JW, Bemiller SM, Murtishaw AS et al (2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y) 4:575–590CrossRef
5.
Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease–a double-edged sword. Neuron 35:419–432PubMedCrossRef
6.
Simard AR, Rivest S (2006) Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer’s disease. Mol Psychiatry 11:327–335PubMedCrossRef
7.
Stalder AK, Ermini F, Bondolfi L et al (2005) Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci 25:11125–11132PubMedPubMedCentralCrossRef
8.
Bradburn S, Murgatroyd C, Ray N (2019) Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a meta-analysis. Ageing Res Rev 50:1–8PubMedCrossRef
9.
Sayed A, Bahbah EI, Kamel S et al (2020) The neutrophil-to-lymphocyte ratio in Alzheimer’s disease: current understanding and potential applications. J Neuroimmunol 349:577398PubMedCrossRef
10.
Akıl E, Bulut A, Kaplan İ et al (2015) The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson’s disease. Neurol Sci 36:423–428PubMedCrossRef
11.
Alexander GE (2004) Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin Neurosci 6:259–280PubMedPubMedCentralCrossRef
12.
Djaldetti R, Lev N, Melamed E (2009) Lesions outside the CNS in Parkinson’s disease. Mov Disord 24:793–800PubMedCrossRef
13.
Hannoodee S, Nasuruddin DN (2020) Acute ınflammatory response. In: StatPearls [Internet] Treasure Island (FL): StatPearls Publishing
14.
Pahwa R, Goyal A, Bansal P, Jialal I (2020) Chronic inflammation. In: StatPearls [Internet] Treasure Island (FL): StatPearls Publishing
15.
Petrone AB, Eisenman RD, Steele KN et al (2019) Temporal dynamics of peripheral neutrophil and lymphocytes following acute ischemic stroke. Neurol Sci 40:1877–1885PubMedPubMedCentralCrossRef
16.
Uçar CA, Çokal BG, Artık HAÜ et al (2017) Comparison of neutrophil-lymphocyte ratio (NLR) in Parkinson’s disease subtypes. Neurol Sci 38:287–293CrossRef
17.
İmtiaz F, Shafique K, Mirza SS et al (2012) Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. IntArchMed 5:2
18.
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:263–269PubMedPubMedCentralCrossRef
19.
Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:2412–2414PubMedCrossRef
20.
Hughes AJ, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedPubMedCentralCrossRef
21.
22.
23.
Rubio-Perez JM, Morillas-Ruiz JM (2012) A review: inflammatory process in Alzheimer’s disease, role of cytokines. Sci World J 2012:756357CrossRef
24.
25.
Cappellano G, Carecchio M, Fleetwood T et al (2013) Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis 2:89–107PubMedPubMedCentral
26.
27.
28.
Ferretti MT, Cuello AC (2011) Does a pro-inflammatory process precede Alzheimer’s disease and mild cognitive impairment? Curr Alzheimer Res 8:164–174PubMedCrossRef
29.
Strang F, Scheichl A, Chen YC et al (2012) Amyloid plaques dissociate pentameric to monomeric C-reactive protein: a novel pathomechanism driving cortical inflammation in Alzheimer’s disease? Brain Pathol 22:337–346PubMedCrossRef
30.
31.
McColl BW, Rothwell NJ, Allan SM (2007) Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci 27:4403–4412PubMedPubMedCentralCrossRef
32.
Heppner F, Ransohoff R, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16:358–372PubMedCrossRef
33.
Zotova E, Nicoll JA, Kalaria R, Holmes C et al (2010) Inflammation in Alzheimer’s disease: relevance to pathogenesis and therapy. Alzheimers Res Ther 2:1PubMedPubMedCentralCrossRef
34.
Sultana R, Baglioni M, Cecchetti R et al (2013) Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease. Free Radic Biol Med 65:595–606PubMedCrossRef
35.
36.
Llanos-Gonzalez E, Henares-Chavarino AA, Pedrero-Prieto CM et al (2019) Interplay between mitochondrial oxidative disorders and proteostasis in Alzheimer’s disease. Front Neurosci 13:1444PubMedCrossRef
37.
Miller VM, Lawrence DA, Mondal TK et al (2009) Reduced glutathione is highly expressed in white matter and neurons in the unperturbed mouse brain—implications for oxidative stress associated with neurodegeneration. Brain Res 1276:22–30PubMedPubMedCentralCrossRef
38.
Wilkinson BL, Landreth GE (2006) The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer’s disease. J Neuroinflammation 3:30PubMedPubMedCentralCrossRef
39.
Kuyumcu ME, Yesil Y, Oztürk ZA et al (2012) The evaluation of neutrophil-lymphocyte ratio in Alzheimer’s disease. Dement Geriatr Cogn Disord 34:69–74PubMedCrossRef
40.
Shad KF, Aghazadeh Y, Ahmad S et al (2013) Peripheral markers of Alzheimer’s disease: surveillance of white blood cells. Synapse 67:541–543PubMedCrossRef
41.
Rembach A, Watt AD, Wilson WJ et al (2014) An increased neutrophil-lymphocyte ratio in Alzheimer’s disease is a function of age and is weakly correlated with neocortical amyloid accumulation. J Neuroimmunol 273:65–71PubMedCrossRef
42.
43.
44.
45.
Liu B, Gao HM, Hong JS (2003) Parkinson’s disease and exposure to ınfectious agents and pesticides and the occurrence of brain ınjuries: role of neuroinflammation. Environ Health Perspect 111:1065–1073PubMedPubMedCentralCrossRef
46.
Martin-Bastida A, Tilley BS, Bansal S et al (2021) Iron and inflammation: in vivo and post-mortem studies in Parkinson’s disease. J Neural Transm 128:15–25PubMedCrossRef
47.
Ramsey CP, Tansey MG (2014) A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson’s disease and potential molecular targets. Exp Neurol 256:126–132PubMedCrossRef
48.
Collins LM, Toulouse A, Connor TJ et al (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 62:2154–2168PubMedCrossRef
49.
Herrera A, Muñoz P, Steinbusch H et al (2017) Are dopamine oxidation metabolites involved in the loss of dopaminergic neurons in the nigrostriatal system in Parkinson’s disease? ACS Chem Neurosci 8:702–711PubMedCrossRef
50.
Lotharius J, Brundin P (2002) Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3:932–942PubMedCrossRef
51.
Song IU, Kim YD, Cho HJ (2013) Is neuroinflammation involved in the development of dementia in patients with Parkinson’s disease? Intern Med 52:1787–1792PubMedCrossRef
52.
Singh A, Tripathi P, Singh S (2021) Neuroinflammatory responses in Parkinson’s disease: relevance of Ibuprofen in therapeutics. Inflammopharmacology 29:5–14PubMedCrossRef
53.
54.
Solmaz V, Pekdaş EG, Aksoy D et al (2018) Serum neutrophil-lymphocyte ratios, C-reactive protein and sedimentation levels in Parkinson’s disease. Cukurova Med J 43:305–311CrossRef
55.
Jin H, Gu HY, Mao CJ et al (2020) Association of inflammatory factors and aging in Parkinson’s disease. Neurosci Lett 736:135259PubMedCrossRef
56.
Moghaddam HS, Sherbaf FG, Zadeh MM et al (2018) Association between peripheral inflammation and DATSCAN data of the striatal nuclei in different motor subtypes of Parkinson disease. Front Neurol 9:234CrossRef
57.
Karuppagounder SS, Madathil SK, Pandey M et al (2013) Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson’s disease in rats. Neuroscience 236:136–148PubMedCrossRef
58.
Ahn TB, Jeon BS (2015) The role of quercetin on the survival of neuron-like PC12 cells and the expression of α-synuclein. Neural Regen Res 10:1113–1119PubMedPubMedCentralCrossRef
59.
Wang J, Song Y, Chen Z et al (2018) Connection between systemic ınflammation and neuroinflammation underlies neuroprotective mechanism of several phytochemicals in neurodegenerative diseases. Oxid Med Cell Longev 2018:1972714PubMedPubMedCentralCrossRef
60.
Parlar A, Annac E, Arslan SO et al (2021) Pretreatment with glabridin prevents carrageenan-ınduced ınflammation: the roles for cytokines and oxidative stress production. Farmacia 69:135–141CrossRef
61.
Mandegary A, Saeedi A, Eftekhari A et al (2013) Hepatoprotective effect of silyamarin in individuals chronically exposed to hydrogen sulfide; modulating influence of TNF-α cytokine genetic polymorphism. Daru 21:28PubMedPubMedCentralCrossRef
Metadata
Title
Investigation of the peripheral inflammation (neutrophil–lymphocyte ratio) in two neurodegenerative diseases of the central nervous system
Authors
Sonat Pınar Kara
Bengü Altunan
Aysun Unal
Publication date
01-03-2022
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 3/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05507-5

Other articles of this Issue 3/2022

Neurological Sciences 3/2022 Go to the issue

Original Article

Depressive symptoms in patients with epilepsy and clinically associated features in a single tertiary center

Original Article

Epidemiology, management and outcome of status epilepticus in adults: single-center Italian survey

Original Article

Progressive supranuclear palsy with marked ventricular dilatation mimicking normal pressure hydrocephalus

Original Article

Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy?

COVID-19

Massive cerebral venous sinus thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 serum: case report of a successful multidisciplinary approach

Letter to the Editor

The use of pharmacologic prophylaxis for migraine in pediatric and adolescent age: a crucial concern